Cipla Viraday Tablets

Cipla Viraday tablets are antiretroviral medicines used in the management of human immunodeficiency virus (HIV) infection as part of combination therapy. Viraday is a fixed-dose combination containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate, which work together to help suppress HIV viral replication and support long-term viral load control under medical supervision.

This combination therapy is widely used due to its once-daily dosing convenience and effectiveness in maintaining immune system function. Cipla Viraday Tablets help reduce the progression of HIV infection when taken consistently as prescribed by a healthcare professional, supporting improved treatment adherence and outcomes.

This product supports constant therapeutic performance by adhering to accepted quality and safety requirements. Cipla Viraday Tablets are a reliable pharmaceutical product with pharmaceutical-grade quality that makes a substantial contribution to contemporary pharmaceutical antiretroviral treatment approaches.

Product Features

• Fixed-dose combination antiretroviral therapy
• Contains Efavirenz, Emtricitabine, and Tenofovir
• Used for effective HIV infection management
• Once-daily oral tablet for convenient dosing
• Pharmaceutical-grade quality standards

How It Helps

• Helps suppress HIV viral replication
• Supports long-term control of HIV infection
• Assists in maintaining immune system strength
• Reduces the risk of HIV disease progression
• Supports consistent and simplified treatment regimens